Screener
Cytek Biosciences, Inc. CTKB Business Segments — Sales (excluding stock-based compensation)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept ctkb:SellingAndMarketingExpenseExcludingShareBasedPaymentArrangementExpense.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue, net | $48,140 | $45,602 | $92,275 | $87,059 |
| Cost of sales (excluding stock-based compensation) | 18,584 | 20,144 | 40,255 | 39,865 |
| Amortization - license & IP expense | 481 | 481 | 962 | 974 |
| Sales (excluding stock-based compensation) | 9,042 | 7,832 | 17,855 | 16,438 |
| Marketing (excluding stock-based compensation) | 3,357 | 3,066 | 5,411 | 5,765 |
| Research and development (excluding stock-based compensation) | 8,649 | 7,403 | 17,290 | 15,551 |
| General and administrative (excluding stock-based compensation) | 14,088 | 10,509 | 30,166 | 20,644 |
| Stock-based compensation expense | 5,339 | 6,791 | 10,200 | 13,421 |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation)?
- Cytek Biosciences, Inc. (CTKB) reported business segments — sales (excluding stock-based compensation) of $9.04M in Q2 2026.
- How has Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation) changed year-over-year?
- Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation) increased by 15.4% year-over-year, from $7.83M to $9.04M.
- What is the long-term trend for Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation)?
- Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation) has grown at a 25.9% compound annual growth rate (CAGR), from $17.12M to $34.17M.
- What does business segments — sales (excluding stock-based compensation) mean?
- Captures the cash-based operating expenses associated with the sales and distribution functions of the segment. It provides insight into the cost structure required to acquire and retain customers while excluding the impact of equity-based incentives.
Ask your AI about Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude